Alkermes PLC (NASDAQ:ALKS) Director Richard F. Pops sold 50,000 shares of Alkermes PLC stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $48.87, for a total value of $2,443,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Alkermes PLC (ALKS) traded up $2.34 during trading hours on Friday, reaching $50.99. The company’s stock had a trading volume of 956,093 shares, compared to its average volume of 971,668.

Alkermes PLC (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative return on equity of 7.27% and a negative net margin of 20.12%. The company had revenue of $217.40 million for the quarter, compared to analyst estimates of $231.29 million. During the same period last year, the company posted ($0.09) earnings per share. The firm’s revenue was up 20.6% compared to the same quarter last year. analysts anticipate that Alkermes PLC will post -0.59 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/11/03/alkermes-plc-alks-director-richard-f-pops-sells-50000-shares.html.

Several hedge funds and other institutional investors have recently made changes to their positions in ALKS. Janus Henderson Group PLC increased its position in shares of Alkermes PLC by 13,784.0% during the second quarter. Janus Henderson Group PLC now owns 2,330,992 shares of the company’s stock worth $135,128,000 after acquiring an additional 2,314,203 shares during the last quarter. Fiera Capital Corp purchased a new stake in shares of Alkermes PLC during the second quarter worth about $37,717,000. Vanguard Group Inc. increased its position in shares of Alkermes PLC by 3.7% during the second quarter. Vanguard Group Inc. now owns 12,546,198 shares of the company’s stock worth $727,303,000 after acquiring an additional 449,563 shares during the last quarter. First Trust Advisors LP increased its position in shares of Alkermes PLC by 37.6% during the second quarter. First Trust Advisors LP now owns 979,813 shares of the company’s stock worth $56,800,000 after acquiring an additional 267,742 shares during the last quarter. Finally, Woodford Investment Management Ltd increased its position in shares of Alkermes PLC by 2.4% during the second quarter. Woodford Investment Management Ltd now owns 7,647,977 shares of the company’s stock worth $443,353,000 after acquiring an additional 177,449 shares during the last quarter. 98.74% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts recently weighed in on the company. J P Morgan Chase & Co set a $78.00 target price on Alkermes PLC and gave the company a “buy” rating in a report on Friday, October 27th. UBS AG set a $54.00 target price on Alkermes PLC and gave the company a “hold” rating in a report on Friday, October 27th. Credit Suisse Group reduced their target price on Alkermes PLC from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. Barclays PLC set a $50.00 target price on Alkermes PLC and gave the company a “hold” rating in a report on Thursday, October 26th. Finally, Citigroup Inc. set a $62.00 target price on Alkermes PLC and gave the company a “hold” rating in a report on Thursday, October 26th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $63.55.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.